Referenzen
Produkte Transfektion
Kostenlose Testsamples
Anwendungshinweise:
Im „Transfection Reagent Selection Guide“ können Sie durch Filterfunktionen z.B. für Ihre Kombination aus zu transfizierender Zelle und Nukleinsäure die Liste vorhandener Referenzen durchsuchen. Ebenso können Sie im Feld „Referenzen durchsuchen“ am Anfang der Seite mit passenden Schlagwörtern zu einem Ergebnis gelangen. Eine Referenz zeigt an, dass das gefundene Transfektionsreagenz bereits erfolgreich für die entsprechende Anwendung verwendet wurde. Im Idealfall sind getestete Transfektionsparameter und Transfektionseffizienzen angegeben.
Keine Referenz? > Allgemeine Auswahlhilfe
Wenn Sie keine Referenz gefunden haben, heißt das nicht, dass kein passendes Reagenz zur Verfügung steht, sondern lediglich, dass bisher keine Erfahrungsberichte vorliegen. In diesem Falle kann durch eine Vorauswahl ein erfolgsversprechendes Transfektionsreagenz ausgewählt (Allgemeine Auswahlhilfe) und letztendlich ausgetestet (Kostenlose Testsamples) werden. Wenn Sie einen Erfahrungsbericht für uns schreiben möchten machen wir Ihnen ein Angebot für eine Gegenleistung.
CELL TYPE | DESCRIPTION OF CELL TYPE | CAT.NO. | SPECIES | ORIGIN OF CELLS | COMMON CELL TYPE | GROWTH PROPERTIES | NUCLEIC ACID / DELIVERED MOLECULE | APPLICATION | PRODUCT | REFERENCE TYPE | BIBLIOGRAPHIC DATA | LINK | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
WS-15 |
Human breast cancer cell line | Human | breast | cell line | plasmid | RNA-Interference | Metafectene | publication | M. P.V. Shekhar et al., Cancer Res., Mar 2008; 68: 1741 - 1750 | Link | |||
TAM6 |
Human breast adenocarcinoma cell line (MCF-7 clone) | Human | breast | cell line | adherent | miRNA | K2 Transfection System | publication | B. Ljepoja et al.,The Breast, 2019, 43: 31-38, doi.org/10.1016/j.breast.2018.10.007 | Link | |||
TAM6 |
Human breast adenocarcinoma cell line (MCF-7 clone) | Human | breast | cell line | adherent | plasmid | K2 Transfection System | publication | B. Ljepoja et al.,The Breast, 2019, 43: 31-38, doi.org/10.1016/j.breast.2018.10.007 | Link | |||
T-47D |
Human breast cancer cel line | ATCC HTB-133 | Human | breast | cell line | adherent | miRNA | K2 Transfection System | publication | B. Ljepoja et al.,The Breast, 2019, 43: 31-38, doi.org/10.1016/j.breast.2018.10.007 | Link | ||
T-47D |
Human breast cancer cel line | ATCC HTB-133 | Human | breast | cell line | adherent | siRNA | RNA-Interference | Metafectene PRO | publication | C. Thirukkumaran et al., PLOSONE 2017, DOI:10.1371/journal.pone.0168233 | Link | |
T-47D |
Human breast cancer cel line | ATCC HTB-133 | Human | breast | cell line | adherent | plasmid | K2 Transfection System | publication | B. Ljepoja et al.,The Breast, 2019, 43: 31-38, doi.org/10.1016/j.breast.2018.10.007 | Link | ||
T-47D |
Human breast cancer cel line | ATCC HTB-133 | Human | breast | cell line | adherent | siRNA | RNA-Interference | Metafectene PRO | publication | I. H. Polat, Doctoral Thesis, 2016, University of Barcelona | Link | |
SkBr3 |
Human EpCAM-positive breast adenocarcinoma cell line | ATCC HTB-30 | Human | breast | cell line | adherent | siRNA | RNA-Interference | Metafectene | publication | N. Golkar et al., Int. J. of Pharmaceutics, 2016, 510: 30-41; doi.org/10.1016/j.ijpharm.2016.06.026 | ||
SKBR3 |
Human EpCAM-positive breast adenocarcinoma cell line | ATCC HTB-30 | Human | breast | cell line | adherent | oligonucleotide | DOTAP | publication | M. M. M. Enriquez ez al., PLoSONE13(11):e0206818, doi.org/10.1371/journal.pone.0206818 | Link | ||
SkBr3 |
Human EpCAM-positive breast adenocarcinoma cell line | ATCC HTB-30 | Human | breast | cell line | adherent | siRNA | RNA-Interference | Metafectene | publication | N. Golkar et al., Data in Brief, 2016, 8:1018-1023; doi.org/10.1016/j.dib.2016.06.064 | Link | |
SkBr3 |
Human EpCAM-positive breast adenocarcinoma cell line | ATCC HTB-30 | Human | breast | cell line | adherent | oligonucleotide | Metafectene | publication | C. Cava et al., Theranostics, 2020, 10(1): 50-61. doi: 10.7150/thno.36274 | Link | ||
SkBr3 |
Human EpCAM-positive breast adenocarcinoma cell line | ATCC HTB-30 | Human | breast | cell line | adherent | plasmid | stable transfection | Metafectene | publication | O. Gires et al., Anticancer Res, Nov 2004; 24: 3715 - 3722 | Link | |
SKBr3 |
Human EpCAM-positive breast adenocarcinoma cell line | ATCC HTB-30 | Human | breast | cell line | adherent | plasmid | Metafectene PRO | publication | H.-K. Lee, PhD Thesis, 2015, Seoul National University | Link | ||
SkBr3 |
Human EpCAM-positive breast adenocarcinoma cell line | ATCC HTB-30 | Human | breast | cell line | adherent | iron oxide | Metafectene | publication | L. Matuszewski et al., Radiology, Apr 2005; 235: 155 - 161 | |||
SKBR3 |
Human EpCAM-positive breast adenocarcinoma cell line | ATCC HTB-30 | Human | breast | cell line | adherent | oligonucleotide | Metafectene | publication | C. Cava et al., Theranostics, 2020, 10(1): 50-61, doi: 10.7150/thno.36274 | Link | ||
SKBR3 |
Human EpCAM-positive breast adenocarcinoma cell line | ATCC HTB-30 | Human | breast | cell line | adherent | oligonucleotide | DOTAP | publication | A. Avinó et al., Protocols in Nucleic Acid Chemistry, 2020, 77: e78, doi: 10.1002/cpnc.78 | |||
SKBR3 |
Human EpCAM-positive breast adenocarcinoma cell line | ATCC HTB-30 | Human | breast | cell line | adherent | oligonucleotide | Metafectene | publication | A. M. Tamaddona et al., Iranian J. of Pharm. Sci., 2011, 11: 7(2): 79-87 | Link | ||
SkBr3 |
Human EpCAM-positive breast adenocarcinoma cell line | ATCC HTB-30 | Human | breast | cell line | adherent | plasmid | Metafectene PRO | publication | A. M. Scherbakov et al., Acta Naturae, 2015, 7(3): 133-1309 | Link | ||
NMuMG |
Mouse mammary gland cell line | ATCC CRL-1636 | Mouse | breast | cell line | adherent | plasmid | Metafectene PRO | publication | K. Konopka et al., Cell Mol Biol Lett, Jan 2009; 14(1): 70-89 | |||
MDA-MB-468 |
Human breast adenocarcinoma cell line | ATCC HTB-132 | Human | breast | cell line | adherent | plasmid | Metafectene PRO | publication | A. Ray et al., Mol. Cancer Res., Aug 2011; 9: 1030 - 1041 | Link | ||
MDA-MB-468 |
Human breast adenocarcinoma cell line | ATCC HTB-132 | Human | breast | cell line | adherent | oligonucleotide | DOTAP | publication | A. Avinó et al., Protocols in Nucleic Acid Chemistry, 2020, 77: e78, doi: 10.1002/cpnc.78 | |||
MDA-MB-436 |
Human breast cancer cell line | Human | breast | cell line | adherent | plasmid | stable transfection | Metafectene PRO | publication | L. J. Barlow, Dissertation, 2020, University Graduate School | Link | ||
MDA-MB-436 |
Human breast cancer cell line | Human | breast | cell line | adherent | plasmid | cotransfection (plasmid/plasmid) | Metafectene PRO | publication | L. J. Barlow, Dissertation, 2020, University Graduate School | Link | ||
MDA-MB-435S |
Human breast cancer cell line | ATCC HTB-129 | Human | breast | cell line | adherent | siRNA | RNA-Interference | Metafectene PRO | publication | K. Kemppainen et al., Cellular Signalling, 2016, 28: 1894–1903; doi.org/10.1016/j.cellsig.2016.09.004 | ||
MDA-MB-231 |
Human breast adenocarcinoma cell line | ATCC HTB-26 | Human | breast | cell line | adherent | plasmid | Metafectene PRO | publication | H.-K. Lee, PhD Thesis, 2015, Seoul National University | Link |